HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology

Context: ERBB2 (erb-b2 receptor tyrosine kinase 2 or HER2) is currently the only biomarker established for selection of a specific therapy for patients with advanced gastroesophageal adenocarcinoma (GEA). However, there are no comprehensive guidelines for the assessment of HER2 in patients with GEA....

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Am J Clin Pathol
Autores principales: Bartley, Angela N., Washington, Mary Kay, Ventura, Christina B., Ismaila, Nofisat, Colasacco, Carol, Benson, Al B., Carrato, Alfredo, Gulley, Margaret L., Jain, Dhanpat, Kakar, Sanjay, Mackay, Helen J., Streutker, Catherine, Tang, Laura, Troxell, Megan, Ajani, Jaffer A.
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2016
Materias:
Review Articles
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6272805/
https://ncbi.nlm.nih.gov/pubmed/28077399
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ajcp/aqw206
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares